Standout Papers
- Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival (2008)
- Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer (2019)
- Theranostics and artificial intelligence: new frontiers in personalized medicine (2024)
- Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials (2019)
Immediate Impact
9 from Science/Nature 61 standout
Citing Papers
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
Diabetes mellitus—Progress and opportunities in the evolving epidemic
2024 Standout
Works of Þorvarður R. Hálfdánarson being referenced
Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review
2021
Obesity adversely affects survival in pancreatic cancer patients
2010
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Þorvarður R. Hálfdánarson | 4124 | 3033 | 1753 | 258 | 6.1k | |
| Gabriele Capurso | 4197 | 2942 | 1312 | 259 | 7.0k | |
| Thomas Aparicio | 3417 | 1425 | 521 | 242 | 6.2k | |
| Steven N. Hochwald | 3105 | 1101 | 611 | 208 | 7.2k | |
| C G Moertel | 5565 | 2030 | 1349 | 77 | 7.5k | |
| Eugene A. Woltering | 2398 | 2785 | 1912 | 160 | 4.4k | |
| Romain Coriat | 2614 | 1086 | 377 | 285 | 5.0k | |
| Allan J. Schutt | 1994 | 1107 | 647 | 86 | 3.8k | |
| Manal M. Hassan | 5735 | 5648 | 2542 | 154 | 10.0k | |
| Joseph Rubin | 5449 | 4206 | 3151 | 97 | 8.4k | |
| Nipun B. Merchant | 4849 | 1108 | 476 | 209 | 7.5k |
All Works
Login with ORCID to disown or claim papers
Loading papers...